The day in pharma, read in minutes.
NewsEMA CHMP Recommends Seven Medicines at November 2026 Meeting
CHMP recommends seven new medicines at November 2026 meeting, including two insulin aspart biosimilars and generic ruxolitinib, advancing EU market entry timelines.
Reviva Secures USPTO Track 1 Review for Brilaroxazine

Sutro Biopharma Advances Three ADC Programs Toward Clinic

Immix Biopharma Appoints Dual SVPs Ahead of NXC-201 BLA

Codexis Achieves 100-Gram Oligonucleotide Scale-Up

Latest news
11 storiesEros Apothecary Recalls Honey Supplement Over Tadalafil
Eros Apothecary recalls honey supplement after FDA lab testing detects undeclared tadalafil, flagging e-commerce supply chain oversight gaps.

Artelo Reports 40% Weight Loss with Semaglutide in Mice
Artelo's ART27.13 achieves ~40% weight loss combined with semaglutide in nonclinical model; U.S. patent protection expected through 2041.

Grace Therapeutics Advances Dual-Source CMO Strategy
Grace Therapeutics pursues dual-source CMO strategy for GTx-104 after FDA CRL flags CMC deficiencies, with NDA resubmission tied to whichever site clears readiness first.

Monopar Therapeutics Nears Rolling NDA Completion for ALXN1840
Monopar's rolling NDA for ALXN1840 in Wilson disease nears completion, with Phase 3 baseline data and six-year safety findings now on record.

Kiora Pharmaceuticals Advances KIO-401 IND Pathway
Kiora Pharmaceuticals submits Type B pre-IND request for KIO-401, a calpain inhibitor backed by Japanese Phase 2/3 data, targeting CRAO.

Johnson & Johnson Secures Second Phase 3 Win for CAPLYTA
J&J's CAPLYTA meets primary YMRS endpoint in a second Phase 3 trial, clearing the clinical bar for an sNDA filing in bipolar I mania.

FDA Finalizes GFI 273 on Antimicrobial Use in Food Animals
FDA's GFI #273 sets duration-of-use recommendations for veterinary antimicrobials, raising the compliance bar for animal drug sponsors.

ProQR Therapeutics Advances RNA Editing Pipeline
ProQR reports full enrollment in AX-0811 Phase 1 cohorts and targets multiple clinical milestones through H1 2027, with €103M cash runway into mid-2028.

FibroBiologics Expands Patent Portfolio to 170 Issued Patents
FibroBiologics reaches 170 issued patents covering fibroblast therapeutics and manufacturing methods, raising IP complexity for CDMOs entering the space.

Dr. Reddy's Secures Brazil Approval for Generic Semaglutide
ANVISA clears Dr. Reddy's generic semaglutide injection for type 2 diabetes, opening a referenceable regulatory pathway for GLP-1 generics in Brazil.

Janssen Wins Full FDA Approval for Erdafitinib
Janssen's erdafitinib converts to full FDA approval in FGFR3-altered urothelial carcinoma, narrowing the indication and reshaping CDx and labeling obligations.

Worth your time this week

FDA Approves Ensartinib for ALK-Positive Metastatic NSCLC

Checkpoint Therapeutics Gains FDA Approval for Cosibelimab-ipdl

Janssen Gains Traditional FDA Approval for Rybrevant in NSCLC
